Straits Times Index
3,275.62 -12.13 (-0.37%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,109.90 +31.04 (+0.38%) Bitcoin USD
64,431.66 +517.73 (+0.81%) CMC Crypto 200
1,389.57 -6.96 (-0.50%)
Quanterix Corporation (QTRX)
After hours:
| Previous close | 16.04 |
| Open | 15.66 |
| Bid | 15.57 x 700 |
| Ask | 15.63 x 100 |
| Day's range | 15.42 - 15.99 |
| 52-week range | 11.83 - 29.70 |
| Volume | |
| Avg. volume | 362,635 |
| Market cap | 596.272M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.80 |
Simply Wall St.Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain
Quanterix Corporation ( NASDAQ:QTRX ) shareholders might be concerned after seeing the share price drop 13% in the last...
Business WireQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
BILLERICA, Mass., March 21, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in
ZacksQuanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
